Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M. Viale G, et al. Among authors: montagna e. Breast Cancer Res Treat. 2009 Jul;116(2):317-28. doi: 10.1007/s10549-008-0206-z. Epub 2008 Oct 7. Breast Cancer Res Treat. 2009. PMID: 18839307 Clinical Trial.
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.
Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A. Colleoni M, et al. Among authors: montagna e. Breast Cancer Res Treat. 2009 Jul;116(2):359-69. doi: 10.1007/s10549-008-0223-y. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941889 Clinical Trial.
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M. Balduzzi A, et al. Among authors: montagna e. Anticancer Drugs. 2009 Mar;20(3):197-203. doi: 10.1097/CAD.0b013e3283264719. Anticancer Drugs. 2009. PMID: 19182679
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
Gilardi L, De Cicco C, Colleoni M, Cardillo A, Montagna E, Dellapasqua S, Galimberti V, Bagnardi V, Paganelli G. Gilardi L, et al. Among authors: montagna e. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1834-41. doi: 10.1007/s00259-010-1494-1. Epub 2010 Jun 10. Eur J Nucl Med Mol Imaging. 2010. PMID: 20533032 Clinical Trial.
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Montagna E, et al. Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13. Breast Cancer Res Treat. 2010. PMID: 20625816
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: montagna e. Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16. Breast. 2011. PMID: 20638282 Free article.
The TNM classification of breast cancer: need for change.
Arnone P, Zurrida S, Viale G, Dellapasqua S, Montagna E, Arnaboldi P, Intra M, Veronesi U. Arnone P, et al. Among authors: montagna e. Updates Surg. 2010 Oct;62(2):75-81. doi: 10.1007/s13304-010-0014-y. Updates Surg. 2010. PMID: 20845013 No abstract available.
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, Cardillo A, Ghisini R, Galimberti V, Veronesi P, Monti S, Luini A, Raviele PR, Mastropasqua MG, Goldhirsch A, Colleoni M. Montagna E, et al. Breast Cancer Res Treat. 2011 Oct;129(3):867-75. doi: 10.1007/s10549-011-1697-6. Epub 2011 Aug 6. Breast Cancer Res Treat. 2011. PMID: 21822638 Clinical Trial.
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M. Dellapasqua S, et al. Among authors: montagna e. Breast. 2012 Jun;21(3):309-13. doi: 10.1016/j.breast.2012.01.015. Epub 2012 Feb 16. Breast. 2012. PMID: 22341133 Free article.
Invasive lobular breast cancer: subtypes and outcome.
Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G. Iorfida M, et al. Among authors: montagna e. Breast Cancer Res Treat. 2012 Jun;133(2):713-23. doi: 10.1007/s10549-012-2002-z. Epub 2012 Mar 8. Breast Cancer Res Treat. 2012. PMID: 22399188
159 results